Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Analysis of SARS-CoV-2 mutations associated with resistance to therapeutic monoclonal antibodies that emerge after treatment
Daniele Focosi, Scott A. McConnell, David J. Sullivan, et al.
Drug Resistance Updates (2023) Vol. 71, pp. 100991-100991
Open Access | Times Cited: 32

Showing 1-25 of 32 citing articles:

Sotrovimab: A Review of Its Efficacy against SARS-CoV-2 Variants
Daniele Focosi, Arturo Casadevall, Massimo Franchini, et al.
Viruses (2024) Vol. 16, Iss. 2, pp. 217-217
Open Access | Times Cited: 20
Target-based drug design strategies to overcome resistance to antiviral agents: opportunities and challenges
Shaoqing Du, Xueping Hu, Luis Menéndez‐Arias, et al.
Drug Resistance Updates (2024) Vol. 73, pp. 101053-101053
Closed Access | Times Cited: 18
An update on the anti-spike monoclonal antibody pipeline for SARS-CoV-2
Daniele Focosi, Massimo Franchini, Arturo Casadevall, et al.
Clinical Microbiology and Infection (2024) Vol. 30, Iss. 8, pp. 999-1006
Closed Access | Times Cited: 16
COVID-19 therapeutics
Daniele Focosi, Massimo Franchini, Fabrizio Maggi, et al.
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 13
SARS-CoV-2 evolution during prolonged infection in immunocompromised patients
Andrew D. Marques, Jevon Graham-Wooten, Ayannah S. Fitzgerald, et al.
mBio (2024) Vol. 15, Iss. 3
Open Access | Times Cited: 12
Potent and broadly neutralizing antibodies against sarbecoviruses elicited by single ancestral SARS-CoV-2 infection
Yu Lei, Yajie Wang, Yuanchen Liu, et al.
Communications Biology (2025) Vol. 8, Iss. 1
Open Access | Times Cited: 1
Clinical and Virological Outcome of Monoclonal Antibody Therapies Across SARS-CoV-2 Variants in 245 Immunocompromised Patients: A Multicenter Prospective Cohort Study
Sammy Huygens, Corine H. GeurtsvanKessel, Arvind Gharbharan, et al.
Clinical Infectious Diseases (2024) Vol. 78, Iss. 6, pp. 1514-1521
Open Access | Times Cited: 7
Deep mutational scanning reveals functional constraints and antibody-escape potential of Lassa virus glycoprotein complex
Caleb R. Carr, Katharine H. D. Crawford, Michael Murphy, et al.
Immunity (2024) Vol. 57, Iss. 9, pp. 2061-2076.e11
Open Access | Times Cited: 7
Estimates of actual and potential lives saved in the United States from the use of COVID-19 convalescent plasma
Quigly Dragotakes, Patrick W. Johnson, Matthew R. Buras, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 41
Open Access | Times Cited: 6
Compositional features analysis by machine learning in genome represents linear adaptation of monkeypox virus
Sen Zhang, Yadan Li, Yurong Cai, et al.
Frontiers in Genetics (2024) Vol. 15
Open Access | Times Cited: 5
Potent and broadly neutralizing antibodies against sarbecoviruses elicited by single ancestral SARS-CoV-2 infection
Lei Yu, Yajie Wang, Yuanchen Liu, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 5
Antibody drugs targeting SARS-CoV-2: Time for a rethink?
Likeng Liang, Bo Wang, Qing Zhang, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 176, pp. 116900-116900
Open Access | Times Cited: 5
Estimates of Actual and Potential Lives Saved in the United States from the use of COVID-19 Convalescent Plasma
Quigly Dragotakes, Patrick W. Johnson, Matthew R. Buras, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 4
Considerations for the development of monoclonal antibodies to address new viral variants in COVID-19
Arturo Casadevall, Scott A. McConnell, Daniele Focosi
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 8, pp. 787-797
Closed Access | Times Cited: 4
Single Monoclonal Antibodies Should Not Be Used for Coronavirus Disease 2019 Therapy: A Call for Antiviral Stewardship
Arturo Casadevall, Daniele Focosi, Liise-anne Pirofski, et al.
Clinical Infectious Diseases (2024) Vol. 79, Iss. 6, pp. 1404-1407
Closed Access | Times Cited: 4
Development of antiviral drugs for COVID-19 in 2025: unmet needs and future challenges
Daniele Focosi, David J. Sullivan, Massimo Franchini
Expert Review of Anti-infective Therapy (2025)
Closed Access
Deep mutational scanning reveals functional constraints and antigenic variability of Lassa virus glycoprotein complex
Caleb R. Carr, Katharine H. D. Crawford, Michael Murphy, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Research Progress on Spike-Dependent SARS CoV-2 Fusion Inhibitors and Small Molecules Targeting the S2 Subunit of Spike
Matthew R. Freidel, Roger S. Armen
(2024)
Open Access | Times Cited: 1
Research Progress on Spike-Dependent SARS-CoV-2 Fusion Inhibitors and Small Molecules Targeting the S2 Subunit of Spike
Matthew R. Freidel, Roger S. Armen
Viruses (2024) Vol. 16, Iss. 5, pp. 712-712
Open Access | Times Cited: 1
Anti-Spike Monoclonal Antibody Monotherapies and Immune Escape Risk Minimization Strategies
Arturo Casadevall, Daniele Focosi
Clinical Infectious Diseases (2024)
Closed Access | Times Cited: 1
Convalescent Plasma and Other Antibody Therapies for Infectious Diseases—Lessons Learned from COVID-19 and Future Prospects
David J. Sullivan
Current topics in microbiology and immunology (2024)
Closed Access | Times Cited: 1
Monoclonal Antibody Therapies Against SARS-CoV-2: Promises and Realities
Daniele Focosi
Current topics in microbiology and immunology (2024)
Closed Access | Times Cited: 1
Molecular and phenotypic characteristics of respiratory syncytial virus isolates recovered from medically vulnerable children: An exploratory analysis of a phase 2/3 randomized, double-blind, palivizumab-controlled trial of nirsevimab (MEDLEY)
Kevin M. Tuffy, Bahar Ahani, Joseph B. Domachowske, et al.
Vaccine (2024) Vol. 42, Iss. 24, pp. 126276-126276
Open Access | Times Cited: 1
Impact analysis of SARS-CoV-2 vaccination in patients treated with monoclonal antibodies: A monocentric experience
Nicola Perrotta, Luigi Angelo Fiorito, Cristiana Leanza, et al.
International Immunopharmacology (2024) Vol. 142, pp. 113101-113101
Open Access | Times Cited: 1
The Role of Convalescent Plasma in COVID-19: A Conclusive Post-Pandemic Review
Massimo Franchini, Daniele Focosi
Life (2023) Vol. 13, Iss. 12, pp. 2322-2322
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top